KemPharm, a clinical-stage speciality pharmaceutical company developing proprietary new molecular entity (NME) prodrugs, has appointed Tracy Woody as Chief Commercial Officer.
Woody brings to KemPharm more than 20 years of commercial experience building businesses for both emerging and established pharmaceutical, biotechnology, and drug delivery companies.
As Chief Commercial Officer, she will join KemPharm's executive management team and take responsibility for leading the commercialisation strategy for the company's NME prodrug pipeline, including KP201/APAP, the company's most advanced product candidate.
The company anticipates submitting a new drug application (NDA) for KP201/APAP to the FDA in the second half of 2015.
Woody was previously Vice President, Sales & Marketing for NextWave Pharmaceuticals, which was acquired by Pfizer in November 2012.
She is also the Founder and Managing Director of TMW Consulting, a consultancy firm working with emerging biotech and medical device companies. As part of her consultancy work, she was acting CEO of RetroJect, a private ophthalmic medical device company focused on the treatment of glaucoma.
Additionally, Woody has held senior sales, marketing and business development roles at Greer Laboratories and ALZA Pharmaceuticals. She began her career at Pfizer in the US Pharmaceuticals Group.
